An observational study in Choledochal Cyst, sponsored by Beijing Tsinghua Chang Gung Hospital. Not yet recruiting at 1 site in China. Per ClinicalTrials.gov, last updated 2025-12-09.
Sponsored by Beijing Tsinghua Chang Gung Hospital · Observational
This study is an observational cohort study aimed at continuously enrolling patients with biliary dilatation and healthy controls. It will collect bile duct tissue samples and clinical data from participants across all age groups to establish a comprehensive cohort for biliary dilatation research. Based on this cohort, the study seeks to investigate the molecular mechanisms underlying biliary dilatation development and progression, explore the role of host-microbiome interactions in disease processes, and identify biomarkers associated with complications and malignancy risk, to establish evidence-based strategies for improved diagnosis and treatment of biliary dilatation.
Biliary dilatation (BD) is a complex bile duct disease that affects people differently around the world. In Asia, about 1 in every 1,000 people have this condition. In Europe and America, it is much less common, affecting about 1 in every 50,000 to 150,000 people.
People with biliary dilatation face serious health risks. Up to 80% of patients develop complications such as bile duct inflammation (cholangitis) and bile duct stones. Even more concerning, about 30% of patients may develop cancer, and this risk increases with age. Even after surgery to remove the affected bile ducts, patients still face ongoing risks. About 35% continue to have problems with gallstones and bile duct inflammation. Their risk of developing cancer remains 120 to 200 times higher than healthy people, with cancer rates reaching 14.9%.
Despite these serious risks, researchers do not fully understand why biliary dilatation happens, how it gets worse over time, or why it leads to so many complications and such high cancer risk. Very few studies have looked at this disease at the molecular level. One study that examined genes did not find typical genetic changes. Other small studies looking at gene activity and proteins were limited by having too few patients and no comparison groups, so they could not find clear biological patterns.
Recent research has shown that bacteria and other microorganisms play important roles in many bile duct diseases, including bile duct stones, inflammation, and cancer. Because these microorganisms affect so many bile duct conditions, we believe they may also be important in biliary dilatation.
This study aims to create two groups of participants: people with biliary dilatation of all ages and a control group of healthy people. We will collect bile duct tissue samples from patients who have surgery to remove diseased bile ducts and from healthy donor bile duct tissue that would otherwise be discarded during organ transplant surgeries.
Through studying these tissue samples, our research team will work to understand how biliary dilatation develops and gets worse, why complications happen, and what role bacteria and other microorganisms play in this disease process.
22 studies on the registry are indexed under Choledochal Cyst; 10 are open to participants now.
This study's planned enrollment of 400 is close to the median of 400 across 14 observational studies indexed under Choledochal Cyst.
Browse Choledochal Cyst studies →Beijing Tsinghua Chang Gung Hospital is the lead sponsor of 108 studies on the registry; 56 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Disease Group: Patients diagnosed with biliary dilatation who are scheduled for surgical resection. These participants represent the primary study population for investigating the molecular mechanisms and microbiome characteristics associated with biliary dilatation.
Control Group: Healthy donor bile duct tissues that are routinely discarded during organ transplantation surgical procedures. These tissues represent normal bile duct samples that are removed as part of standard surgical preparation but are not used for transplantation, serving as healthy controls for comparison of transcriptome and microbiome profiles.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients who have been definitively diagnosed with biliary dilatation and are scheduled for surgical resection (Disease group) Healthy donor bile duct tissues discarded during organ transplantation procedures as part of routine surgical preparation (Control group)
Exclusion Criteria:
Patients with severe systemic diseases that may affect study outcomes (Disease group) Insufficient tissue sample quality or quantity (Disease group) Unavailable or inadequate donor bile duct tissue samples (Control group)
molecular mechanisms
Identification of differentially expressed genes and altered molecular pathways in biliary dilatation through integrated transcriptome analysis of bile duct tissue samples, measured by RNA sequencing and bioinformatics analysis.
Time frame: At the time of surgery.
Plan to share: No
No publications or documents are linked to this record.
Start is estimated for Dec 2025; primary completion for Jun 2026, 5 months later.
How these figures are worked out, and which studies are left out of them.
This study is not yet recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Beijing Tsinghua Chang Gung Hospital →